OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
RANCHO CORDOVA, Calif., March 23, 2016 -- Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that Dr. Lars Norgren, MD, Ph.D has joined its Clinical Advisory Board.
Having authored over 500 research publications, Dr. Norgren is an internationally renowned authority on peripheral arterial disease (PAD) and vascular and endovascular surgery, including critical limb ischemia (CLI). He is currently Emeritus Professor at Örebro University, Sweden, and serves as a Steering Committee member on multiple clinical trials. He is also co-director of the Inter-Society Consensus for the Management of PAD projects. Dr. Norgren obtained his M.D. at the Karolinska Institute and Ph.D. at Lund University, before serving as Professor of Surgery at Trondheim and Professor (adjunct) of Surgery at Lund University. He was named Professor and Chair of Surgery at University Hospital Örebro in 2004, where he served until 2010. From 2008-2011, Dr. Norgren served as Director of Research and Member of the Hospital Board at Örebro University. Dr. Norgren will serve as a consultant to Cesca Therapeutics as the Company develops its program for autologous, point-of-care cell therapies focused on the treatment of cardiovascular diseases. Cesca is currently preparing to initiate a U.S. pivotal trial evaluating its SurgWerks™ with VXP platform for the treatment of CLI patients.
“We are delighted that Dr. Norgren has agreed to join our advisory board,” said Cesca Therapeutics’ CEO Robin Stracey. “He will be a valuable resource and will add considerable depth to our clinical team.”
Dr. Norgren added, “It is a pleasure to contribute to the development of clinical therapies such as Cesca’s for the critical unmet needs of vascular degenerative disease, including CLI.”
Critical limb ischemia is an advanced stage of peripheral artery disease that results in an estimated 70,000 major limb amputations in the U.S. every year. Key contributors to the incidence of CLI are diabetes, obesity and smoking.
About Cesca Therapeutics Inc.
Cesca Therapeutics Inc. (www.cescatherapeutics.com) is engaged in the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. The Company is a leader in the development and manufacture of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. These include:
The SurgWerksTM with VXP Platform - proprietary, indication-specific stem cell therapy kits and associated devices, for use at the point-of-care in treating vascular and orthopedic diseases.
The CellWerksTM Platform - a proprietary stem cell laboratory system for processing target cells used in the treatments of oncological and hematological disorders.
The AutoXpress® Platform (AXP®) - a proprietary automated device that includes companion sterile blood processing disposables for harvesting stem cells from cord blood.
The MarrowXpress® Platform (MXP®), a derivative product of the AXP and its accompanying disposable bag set, for the isolation and concentration of stem cells from bone marrow.
The BioArchive® System, an automated cryogenic device used by cord blood banks for the cryopreservation and storage of cord blood stem cell specimens for future use in approved regenerative medicine procedures.
Forward Looking Statement
The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics' forward-looking statements is set forth under the caption "Risk Factors" in Cesca Therapeutics annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
Contact: Cesca Therapeutics Inc. http://www.cescatherapeutics.com Investor Contact: The Ruth Group Lee Roth / Tram Bui 646-536-7012 / 7035 [email protected] / [email protected]
